These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 22246718

  • 1. Preoperative hydronephrosis: independent predictor for changes in renal function following nephroureterectomy.
    Hoshino K, Kikuchi E, Tanaka N, Akita H, Ito Y, Miyajima A, Jinzaki M, Oya M.
    Jpn J Clin Oncol; 2012 Mar; 42(3):202-7. PubMed ID: 22246718
    [Abstract] [Full Text] [Related]

  • 2. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder.
    Dash A, Galsky MD, Vickers AJ, Serio AM, Koppie TM, Dalbagni G, Bochner BH.
    Cancer; 2006 Aug 01; 107(3):506-13. PubMed ID: 16773629
    [Abstract] [Full Text] [Related]

  • 3. Predictive factors for impaired renal function following nephroureterectomy in upper urinary tract urothelial cell carcinoma.
    Rodríguez Faba O, Palou J, Breda A, Maroto P, Fernández Gómez JM, Wong A, Villavicencio H.
    Urol Int; 2014 Aug 01; 92(2):169-73. PubMed ID: 24280761
    [Abstract] [Full Text] [Related]

  • 4. Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy.
    Xylinas E, Rink M, Margulis V, Clozel T, Lee RK, Comploj E, Novara G, Raman JD, Lotan Y, Weizer A, Roupret M, Pycha A, Scherr DS, Seitz C, Ficarra V, Trinh QD, Karakiewicz PI, Montorsi F, Zerbib M, Shariat SF, UTUC Collaboration.
    BJU Int; 2013 Aug 01; 112(4):453-61. PubMed ID: 23464979
    [Abstract] [Full Text] [Related]

  • 5. Prediction of renal function after nephroureterectomy in patients with upper tract urothelial carcinoma.
    Hashimoto T, Ohno Y, Nakashima J, Gondo T, Nakagami Y, Namiki K, Horiguchi Y, Yoshioka K, Ohori M, Tachibana M.
    Jpn J Clin Oncol; 2015 Nov 01; 45(11):1064-8. PubMed ID: 26355160
    [Abstract] [Full Text] [Related]

  • 6. Impact of the CKD-EPI equation for estimating renal function on eligibility for cisplatin-based chemotherapy in patients with urothelial cancer.
    Tsao CK, Moshier E, Seng SM, Godbold J, Grossman S, Winston J, Oh WK, Galsky MD.
    Clin Genitourin Cancer; 2012 Mar 01; 10(1):15-20. PubMed ID: 22130294
    [Abstract] [Full Text] [Related]

  • 7. Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma.
    Messer JC, Terrell JD, Herman MP, Ng CK, Scherr DS, Scoll B, Boorjian SA, Uzzo RG, Wille M, Eggener SE, Lucas SM, Lotan Y, Shariat SF, Raman JD.
    Urol Oncol; 2013 Aug 01; 31(6):904-8. PubMed ID: 21906967
    [Abstract] [Full Text] [Related]

  • 8. Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma.
    Soga N, Arima K, Sugimura Y.
    Int J Urol; 2008 Sep 01; 15(9):800-3. PubMed ID: 18651862
    [Abstract] [Full Text] [Related]

  • 9. Eligibility for neoadjuvant/adjuvant cisplatin-based chemotherapy among radical cystectomy patients.
    Thompson RH, Boorjian SA, Kim SP, Cheville JC, Thapa P, Tarrel R, Dronca R, Costello B, Frank I.
    BJU Int; 2014 May 01; 113(5b):E17-21. PubMed ID: 24006893
    [Abstract] [Full Text] [Related]

  • 10. Renal safety and efficacy of cisplatin-based chemotherapy in patients with a solitary kidney after nephroureterectomy for urothelial carcinoma of the upper urinary tract.
    Cho KS, Joung JY, Seo HK, Cho IC, Chung HS, Chung J, Lee KH.
    Cancer Chemother Pharmacol; 2011 Apr 01; 67(4):769-74. PubMed ID: 20532510
    [Abstract] [Full Text] [Related]

  • 11. Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration.
    Hellenthal NJ, Shariat SF, Margulis V, Karakiewicz PI, Roscigno M, Bolenz C, Remzi M, Weizer A, Zigeuner R, Bensalah K, Ng CK, Raman JD, Kikuchi E, Montorsi F, Oya M, Wood CG, Fernandez M, Evans CP, Koppie TM.
    J Urol; 2009 Sep 01; 182(3):900-6. PubMed ID: 19616245
    [Abstract] [Full Text] [Related]

  • 12. Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer.
    Raj GV, Karavadia S, Schlomer B, Arriaga Y, Lotan Y, Sagalowsky A, Frenkel E.
    Cancer; 2011 Jan 15; 117(2):276-82. PubMed ID: 20830767
    [Abstract] [Full Text] [Related]

  • 13. Preoperative predictors of renal function decline after radical nephroureterectomy for upper tract urothelial carcinoma.
    Kaag M, Trost L, Thompson RH, Favaretto R, Elliott V, Shariat SF, Maschino A, Vertosick E, Raman JD, Dalbagni G.
    BJU Int; 2014 Nov 15; 114(5):674-9. PubMed ID: 24314050
    [Abstract] [Full Text] [Related]

  • 14. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
    Gohji K, Higuchi A, Maruyama S, Minayoshi K, Fujii A, Itoh N, Hasunuma Y, Tanaka H, Izumi T.
    Jpn J Clin Oncol; 1993 Oct 15; 23(5):291-8. PubMed ID: 7693990
    [Abstract] [Full Text] [Related]

  • 15. Hydronephrosis as a prognostic marker in bladder cancer in a cystectomy-only series.
    Bartsch GC, Kuefer R, Gschwend JE, de Petriconi R, Hautmann RE, Volkmer BG.
    Eur Urol; 2007 Mar 15; 51(3):690-7; discussion 697-8. PubMed ID: 16904815
    [Abstract] [Full Text] [Related]

  • 16. Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors.
    Angulo JC, Sanchez-Chapado M, Lopez JI, Flores N.
    J Urol; 1996 Jun 15; 155(6):1897-902. PubMed ID: 8618282
    [Abstract] [Full Text] [Related]

  • 17. The effect of contralateral kidney volume on renal function after radical nephroureterectomy: Implications for eligibility for neoadjuvant chemotherapy for upper tract urothelial cancer.
    Song W, Sung HH, Han DH, Jeong BC, Seo SI, Jeon SS, Lee HM, Choi HY, Jeon HG.
    Urol Oncol; 2017 Mar 15; 35(3):114.e1-114.e7. PubMed ID: 27908680
    [Abstract] [Full Text] [Related]

  • 18. Bladder cancer after nephroureterectomy in patients with urothelial carcinoma of the upper urinary tract.
    Ku JH, Choi WS, Kwak C, Kim HH.
    Urol Oncol; 2011 Mar 15; 29(4):383-7. PubMed ID: 19556154
    [Abstract] [Full Text] [Related]

  • 19. [Impact of different methods of estimating renal function on determining eligibility for cisplatin (CDDP)-based chemotherapy in patients with invasive urothelial carcinoma].
    Goto T, Yoshimura K, Matsui Y, Shimizu Y, Inoue T, Okubo K, Kamba T, Nishiyama H, Ogawa O.
    Hinyokika Kiyo; 2011 Dec 15; 57(12):671-6. PubMed ID: 22240299
    [Abstract] [Full Text] [Related]

  • 20. Formulas calculating creatinine clearance are inadequate for determining eligibility for Cisplatin-based chemotherapy in bladder cancer.
    Raj GV, Iasonos A, Herr H, Donat SM.
    J Clin Oncol; 2006 Jul 01; 24(19):3095-100. PubMed ID: 16809735
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.